Drug Profile
SNS 301
Alternative Names: HAAH vaccine; PAN-301; PAN-301-1; SNS-301Latest Information Update: 09 Jul 2023
Price :
$50
*
At a glance
- Originator Panacea Pharmaceuticals
- Developer Sensei Biotherapeutics
- Class Antineoplastics; Bacteriophages; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer; Myelodysplastic syndromes; Prostate cancer
Most Recent Events
- 02 Jun 2023 Updated efficacy and adverse events data from a phase I/II trial in Squamous cell cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 12 Aug 2021 Sensei Biotherapeutics terminates a phase-I/II clinical trials in Squamous cell cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in USA (Intradermal), due to sponsor's decision (NCT04034225)
- 28 Jun 2021 Discontinued - Clinical-Phase-Unknown for Head and neck cancer (Intradermal)